Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APRIL CAR-T cells in BCMA/TACI+ relapsed/refractory multiple myeloma
NCT04657861Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- May 2022
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of APRIL CAR-T cells in multiple myeloma (MM), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started May 2022; status: recruiting.
02
Drugs
APRIL CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04657861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04657861.